AR122010A1 - Compuestos heterocíclicos como receptores desencadenantes expresados en agonistas de células mieloides 2 y métodos de uso - Google Patents
Compuestos heterocíclicos como receptores desencadenantes expresados en agonistas de células mieloides 2 y métodos de usoInfo
- Publication number
- AR122010A1 AR122010A1 ARP210101218A ARP210101218A AR122010A1 AR 122010 A1 AR122010 A1 AR 122010A1 AR P210101218 A ARP210101218 A AR P210101218A AR P210101218 A ARP210101218 A AR P210101218A AR 122010 A1 AR122010 A1 AR 122010A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- haloalkyl
- halogen
- membered heteroaryl
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 210000000066 myeloid cell Anatomy 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- -1 cyclopent-1-en-1-yl Chemical group 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 2
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 abstract 2
- 101710174937 Triggering receptor expressed on myeloid cells 2 Proteins 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 125000004266 aziridin-1-yl group Chemical group [H]C1([H])N(*)C1([H])[H] 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063019772P | 2020-05-04 | 2020-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122010A1 true AR122010A1 (es) | 2022-08-03 |
Family
ID=78468522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101218A AR122010A1 (es) | 2020-05-04 | 2021-05-04 | Compuestos heterocíclicos como receptores desencadenantes expresados en agonistas de células mieloides 2 y métodos de uso |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US11608344B2 (https=) |
| EP (1) | EP4146222A4 (https=) |
| JP (2) | JP7754846B2 (https=) |
| KR (1) | KR20230019822A (https=) |
| CN (1) | CN115867284A (https=) |
| AR (1) | AR122010A1 (https=) |
| AU (1) | AU2021266805A1 (https=) |
| BR (1) | BR112022022341A2 (https=) |
| CA (1) | CA3182105A1 (https=) |
| CL (1) | CL2022003047A1 (https=) |
| CO (1) | CO2022015930A2 (https=) |
| CR (1) | CR20220560A (https=) |
| CU (1) | CU24735B1 (https=) |
| EC (1) | ECSP22089527A (https=) |
| IL (1) | IL297833A (https=) |
| JO (1) | JOP20220296A1 (https=) |
| MX (1) | MX2022013842A (https=) |
| PE (1) | PE20230846A1 (https=) |
| PH (1) | PH12022552949A1 (https=) |
| TW (1) | TW202208355A (https=) |
| WO (1) | WO2021226629A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7741100B2 (ja) | 2020-05-04 | 2025-09-17 | アムジェン インコーポレイテッド | ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法 |
| TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
| AU2021392813A1 (en) * | 2020-12-04 | 2023-06-29 | Vigil Neuroscience, Inc. | Treatment of diseases related to atp-binding cassette transporter 1 dysfunction using trem2 agonists |
| KR20240026911A (ko) * | 2021-05-04 | 2024-02-29 | 비질 뉴로사이언스 인코포레이티드 | 골수성 세포 2 작용제 상에서 발현되는 유발 수용체로서의 헤테로고리 화합물 및 사용 방법 |
| AR127621A1 (es) * | 2021-11-09 | 2024-02-14 | Vigil Neuroscience Inc | Compuestos heterocíclicos como agonistas del receptor activador expresado en células mieloides 2 y métodos de uso |
| WO2023086800A1 (en) * | 2021-11-09 | 2023-05-19 | Vigil Neuroscience, Inc. | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use |
| EP4430022A4 (en) * | 2021-11-09 | 2025-09-10 | Vigil Neuroscience Inc | HETEROCYCLIC COMPOUNDS USED AS AGONISTS OF THE TRIGGER RECEPTOR EXPRESSED ON MYELOID CELLS 2 AND METHODS OF USE |
| WO2023192288A1 (en) * | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| WO2024233848A1 (en) * | 2023-05-10 | 2024-11-14 | Vigil Neuroscience, Inc. | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use |
| TW202517639A (zh) * | 2023-07-17 | 2025-05-01 | 丹麥商穆納醫療有限責任公司 | Trem2調節劑 |
| TW202542142A (zh) * | 2023-12-12 | 2025-11-01 | 美商維佳神經科學有限公司 | 作為骨髓細胞上表現之觸發受體２促效劑之雜環化合物及其使用方法 |
| WO2025146477A1 (en) | 2024-01-04 | 2025-07-10 | Muna Therapeutics Aps | 2-azetidinyl-7-methyl-8-oxo-6-(trifluoromethyl)-7,8-dihydropyrimido[5,4-d]pyrimidine derivatives derivatives as trem2 modulators for the treatment of neurodegenerative diseases |
| TW202535410A (zh) | 2024-01-04 | 2025-09-16 | 丹麥商穆納醫療有限責任公司 | Ｔｒｅｍ２調節劑 |
| WO2025157993A1 (en) * | 2024-01-24 | 2025-07-31 | Muna Therapeutics Aps | Trem2 modulators |
| WO2026024121A1 (en) * | 2024-07-25 | 2026-01-29 | Yuhan Corporation | Bicyclic fused-ring derivative or salt thereof and pharmaceutical composition including the same |
| WO2026077862A1 (en) * | 2024-10-07 | 2026-04-16 | F. Hoffmann-La Roche Ag | Trem2 agonists |
| WO2026077861A1 (en) * | 2024-10-07 | 2026-04-16 | F. Hoffmann-La Roche Ag | Trem2 agonists |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2940972A (en) | 1957-06-27 | 1960-06-14 | Thomae Gmbh Dr K | Tri-and tetra-substituted pteridine derivatives |
| US2963481A (en) | 1959-11-27 | 1960-12-06 | Smith Kline French Lab | 6-pteridinecarboxylic acid esters |
| US3712892A (en) | 1969-08-02 | 1973-01-23 | Sumitomo Chemical Co | Quinazolinone derivatives |
| JPH05170744A (ja) * | 1991-12-25 | 1993-07-09 | Toray Dow Corning Silicone Co Ltd | 含窒素芳香族複素環式化合物のアルキル化方法 |
| EP0743855A1 (en) | 1994-01-03 | 1996-11-27 | Acea Pharmaceuticals, Inc. | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor |
| DK1028950T3 (da) | 1997-10-28 | 2003-09-01 | Warner Lambert Co | 7-substituerede quinazolin-2,4-dioner nyttige som antibakterielle midler |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| JP2004521892A (ja) | 2000-12-20 | 2004-07-22 | メルク エンド カムパニー インコーポレーテッド | （ハロ−ベンゾカルボニル）複素環縮合フェニル系ｐ３８キナーゼ阻害剤 |
| JP2003005355A (ja) | 2001-06-20 | 2003-01-08 | Fuji Photo Film Co Ltd | 電子線又はｘ線用ネガ型レジスト組成物 |
| JP4690043B2 (ja) | 2002-10-04 | 2011-06-01 | プラナ バイオテクノロジー リミティッド | 神経に対し活性な化合物 |
| GB0229281D0 (en) * | 2002-12-16 | 2003-01-22 | Novartis Ag | Organic compounds |
| WO2005007099A2 (en) | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents |
| PL1673092T3 (pl) | 2003-10-17 | 2008-01-31 | 4 Aza Ip Nv | Pochodne pterydyny podstawione heterocyklem i ich zastosowanie w leczeniu |
| JP2007510642A (ja) * | 2003-11-03 | 2007-04-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 中枢神経系障害の治療のための新規ノルエピネフリン再取込み阻害薬 |
| RU2358969C2 (ru) | 2004-02-13 | 2009-06-20 | Баниу Фармасьютикал Ко., Лтд. | Конденсированное 4-оксопиримидиновое производное |
| WO2005087742A1 (en) * | 2004-03-08 | 2005-09-22 | Exelixis, Inc. | Metabolic kinase modulators and methods of use as pesticides |
| NZ551004A (en) | 2004-04-02 | 2010-07-30 | Prana Biotechnology Ltd | Neurologically-active compounds |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| JP2008531538A (ja) | 2005-02-25 | 2008-08-14 | クドス ファーマシューティカルズ リミテッド | ２，４−ジアミノ−ピリドピリミジン誘導体とｍＴＯＲ阻害剤としてのその使用 |
| US20070032493A1 (en) | 2005-05-26 | 2007-02-08 | Synta Pharmaceuticals Corp. | Method for treating B cell regulated autoimmune disorders |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| KR100659088B1 (ko) | 2005-07-15 | 2006-12-21 | 삼성에스디아이 주식회사 | 디플루오로피리딘계 화합물 및 이를 이용한 유기 발광 소자 |
| JP2009509963A (ja) | 2005-09-23 | 2009-03-12 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
| JP2009528387A (ja) | 2006-03-02 | 2009-08-06 | スミスクライン・ビーチャム・コーポレイション | Ｐｉ３キナーゼ阻害剤として用いるためのチアゾロン |
| US7855194B2 (en) | 2006-03-27 | 2010-12-21 | Hoffmann-La Roche Inc. | Pyrimidine, quinazoline, pteridine and triazine derivatives |
| WO2008003149A2 (en) | 2006-07-06 | 2008-01-10 | Gilead Sciences , Inc. | Substituted pteridines for the treatment and prevention of viral infections |
| US7635683B2 (en) | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
| CA2659851C (en) | 2006-08-23 | 2014-02-25 | Kudos Pharmaceuticals Limited | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
| US8048894B2 (en) | 2007-04-18 | 2011-11-01 | Amgen Inc. | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
| US20090099195A1 (en) | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| MX2010004074A (es) | 2007-10-15 | 2010-07-02 | Astrazeneca Ab | Combinacion 059. |
| WO2009100406A2 (en) | 2008-02-07 | 2009-08-13 | Synta Pharmaceuticals Corp. | Topical formulations for the treatment of psoriasis |
| US8298825B1 (en) | 2008-08-25 | 2012-10-30 | The General Hospital Corporation | TGF-beta receptor inhibitors to enhance direct reprogramming |
| US20120021519A1 (en) | 2008-09-19 | 2012-01-26 | Presidents And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
| WO2010042925A2 (en) | 2008-10-10 | 2010-04-15 | Vm Discovery Inc. | Compositions and methods for treating alcohol use disorders, pain and other diseases |
| WO2010107768A1 (en) | 2009-03-18 | 2010-09-23 | Schering Corporation | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| US8722692B2 (en) | 2009-07-30 | 2014-05-13 | Jianwei Che | Compounds and compositions as Syk kinase inhibitors |
| WO2011014039A1 (en) | 2009-07-31 | 2011-02-03 | Rohm And Haas Electronic Materials Korea Ltd. | Novel organic electroluminescent compounds and organic electroluminescent device using the same |
| US20110124597A1 (en) | 2009-09-25 | 2011-05-26 | Anacor Pharmaceuticals, Inc. | Boron containing small molecules |
| MX2012004846A (es) | 2009-10-29 | 2012-10-05 | Genosco | Inhibidores de cinasa. |
| BR112012022868A2 (pt) * | 2010-03-16 | 2018-06-05 | Merck Patent Gmbh | morfolinilquinazolinas |
| US9139592B2 (en) | 2010-06-14 | 2015-09-22 | Trt Pharma Inc. | Modulators of Nrf2 and uses thereof |
| US10260097B2 (en) | 2011-06-02 | 2019-04-16 | Almac Diagnostics Limited | Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent |
| CN102887895B (zh) | 2011-07-22 | 2016-08-24 | 山东轩竹医药科技有限公司 | 吡啶并嘧啶类mTOR抑制剂 |
| KR101497124B1 (ko) | 2011-11-28 | 2015-03-06 | 덕산네오룩스 주식회사 | 유기전기소자용 화합물, 이를 포함하는 유기전기소자 및 그 전자 장치 |
| SG11201404743TA (en) | 2012-02-08 | 2014-09-26 | Janssen R & D Ireland | Piperidino-pyrimidine derivatives for the treatment of viral infections |
| CN103374021B (zh) | 2012-04-21 | 2015-10-28 | 通化济达医药有限公司 | 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂 |
| WO2014146249A1 (en) * | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors |
| EP3027616B1 (en) | 2013-07-30 | 2018-01-10 | Boehringer Ingelheim International GmbH | Azaindole compounds as modulators of rorc |
| ES2750236T3 (es) | 2013-12-09 | 2020-03-25 | UCB Biopharma SRL | Derivados heteroaromáticos bicíclicos condensados como moduladores de la actividad del TNF |
| KR20150080966A (ko) | 2014-01-02 | 2015-07-13 | 최돈수 | 유기 전기 발광 소자용 발광 재료, 이를 이용한 유기 전기 발광 소자 및 유기 전기 발광 소자용 재료 |
| KR20160060572A (ko) | 2014-11-19 | 2016-05-30 | 주식회사 엠비케이 | 유기 발광 화합물, 잉크 조성물, 유기 발광 소자 및 전자 기기 |
| RU2717665C2 (ru) | 2015-04-15 | 2020-03-24 | Ф. Хоффманн-Ля Рош Аг | Пиридопиримидиноны и их применение в качестве модуляторов рецептора n-метил-d-аспартата |
| US10403826B2 (en) | 2015-05-07 | 2019-09-03 | Universal Display Corporation | Organic electroluminescent materials and devices |
| EP3335254B1 (de) | 2015-08-11 | 2020-04-08 | Merck Patent GmbH | Materialien für organische elektrolumineszenzvorrichtungen |
| WO2017031427A1 (en) | 2015-08-19 | 2017-02-23 | 3-V Biosciences, Inc. | COMPOUNDS AND METHODS FOR INHIBITING mTOR |
| US10573692B2 (en) | 2016-04-06 | 2020-02-25 | Samsung Display Co., Ltd. | Organic light-emitting device having a sealing thin film encapsulation portion |
| KR102606277B1 (ko) | 2016-04-06 | 2023-11-27 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| PL3442947T3 (pl) | 2016-04-15 | 2023-10-02 | Epizyme, Inc. | Związki arylowe lub heteroarylowe podstawione aminą jako inhibitory ehmt1 i ehmt2 |
| MX2019003790A (es) | 2016-10-04 | 2019-09-26 | Enanta Pharm Inc | Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos. |
| US11283028B2 (en) | 2016-10-05 | 2022-03-22 | Rohm And Haas Electronic Materials Korea Ltd. | Organic electroluminescent compound and organic electroluminescent device comprising the same |
| CN109790183A (zh) | 2016-12-13 | 2019-05-21 | 广州华睿光电材料有限公司 | 金属有机配合物及其应用、混合物、有机电子器件 |
| GB201700814D0 (en) | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| TW201843143A (zh) | 2017-03-13 | 2018-12-16 | 德商麥克專利有限公司 | 含有芳基胺結構之化合物 |
| WO2018169352A1 (en) | 2017-03-16 | 2018-09-20 | Rohm And Haas Electronic Materials Korea Ltd. | Organic electroluminescent device |
| KR102335935B1 (ko) | 2017-03-22 | 2021-12-06 | 덕산네오룩스 주식회사 | 유기전기소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치 |
| US20200113901A1 (en) | 2017-03-31 | 2020-04-16 | Epizyme, Inc. | Methods of using ehmt2 inhibitors |
| KR102389204B1 (ko) | 2017-04-18 | 2022-04-21 | 덕산네오룩스 주식회사 | 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치 |
| CN110621316B (zh) | 2017-04-21 | 2024-01-26 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
| WO2018204765A1 (en) | 2017-05-05 | 2018-11-08 | Pairnomix, Llc | Methods of treating epilepsy and kcnq2 related conditions |
| CN110996945A (zh) | 2017-06-13 | 2020-04-10 | 联邦科学技术研究组织 | 抗病毒药物 |
| EP3689866A4 (en) | 2017-09-26 | 2021-07-07 | Nippon Soda Co., Ltd. | QUINOLINE COMPOUND AND BACTERICIDAL AGENT FOR AGRICULTURE AND HORTICULTURE |
| JP2021500326A (ja) | 2017-10-18 | 2021-01-07 | エピザイム，インコーポレイティド | 血液障害の予防又は処置にｅｈｍｔ２阻害剤を使用する方法 |
| AU2018353139A1 (en) | 2017-10-18 | 2020-06-04 | Epizyme, Inc. | Methods of using EHMT2 inhibitors in immunotherapies |
| CN108484680B (zh) | 2018-01-31 | 2020-12-11 | 马鞍山南京大学高新技术研究院 | 一类双硫代芳环/芳杂环磷酸化合物作为辅助配体的铱配合物 |
| CA3098574A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| US12453279B2 (en) | 2018-08-22 | 2025-10-21 | Universal Display Corporation | Organic electroluminescent materials and devices |
| CN109265457A (zh) | 2018-11-01 | 2019-01-25 | 中国药科大学 | 一种利用氧化芳构化构建吡啶并嘧啶二酮骨架的新方法 |
| WO2020231739A2 (en) | 2019-05-10 | 2020-11-19 | Antidote Ip Holdings, Llc | Compounds and methods for treating cancer |
| CN110283171A (zh) | 2019-07-17 | 2019-09-27 | 鼎泰(南京)临床医学研究有限公司 | 一类含有吡啶并嘧啶-4-胺类结构的化合物、药物组合物以及其应用 |
| US11820783B2 (en) | 2019-09-06 | 2023-11-21 | Universal Display Corporation | Organic electroluminescent materials and devices |
| TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
| BR112022022184A2 (pt) | 2020-05-04 | 2023-01-17 | Takeda Pharmaceuticals Co | Derivados de n-(piperidin-4-il)benzamida agindo luminalmente |
| JP7741100B2 (ja) | 2020-05-04 | 2025-09-17 | アムジェン インコーポレイテッド | ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法 |
| IL297864A (en) | 2020-05-04 | 2023-01-01 | Adama Makhteshim Ltd | Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4-dihydropyrimidin-2-one, and methods of use thereof |
| CN111454265B (zh) | 2020-05-07 | 2021-08-24 | 宁波卢米蓝新材料有限公司 | 一种稠杂环化合物及其制备方法和应用 |
| CA3244298A1 (en) | 2022-01-11 | 2023-07-20 | Regeneron Pharmaceuticals, Inc. | TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL VARIANTS 2 (TREM2) AND ITS USES IN THE TREATMENT OF ALZHEIMER'S DISEASE |
-
2021
- 2021-05-03 TW TW110115924A patent/TW202208355A/zh unknown
- 2021-05-04 MX MX2022013842A patent/MX2022013842A/es unknown
- 2021-05-04 PH PH1/2022/552949A patent/PH12022552949A1/en unknown
- 2021-05-04 WO PCT/US2021/070507 patent/WO2021226629A1/en not_active Ceased
- 2021-05-04 CR CR20220560A patent/CR20220560A/es unknown
- 2021-05-04 CU CU2022000064A patent/CU24735B1/es unknown
- 2021-05-04 PE PE2022002567A patent/PE20230846A1/es unknown
- 2021-05-04 KR KR1020227038841A patent/KR20230019822A/ko active Pending
- 2021-05-04 JP JP2022567487A patent/JP7754846B2/ja active Active
- 2021-05-04 IL IL297833A patent/IL297833A/en unknown
- 2021-05-04 BR BR112022022341A patent/BR112022022341A2/pt unknown
- 2021-05-04 AR ARP210101218A patent/AR122010A1/es unknown
- 2021-05-04 CN CN202180047705.7A patent/CN115867284A/zh active Pending
- 2021-05-04 AU AU2021266805A patent/AU2021266805A1/en active Pending
- 2021-05-04 US US17/302,502 patent/US11608344B2/en active Active
- 2021-05-04 CA CA3182105A patent/CA3182105A1/en active Pending
- 2021-05-04 EP EP21800538.7A patent/EP4146222A4/en active Pending
-
2022
- 2022-11-02 JO JOJO/P/2022/0296A patent/JOP20220296A1/ar unknown
- 2022-11-03 CL CL2022003047A patent/CL2022003047A1/es unknown
- 2022-11-04 CO CONC2022/0015930A patent/CO2022015930A2/es unknown
- 2022-11-21 EC ECSENADI202289527A patent/ECSP22089527A/es unknown
- 2022-11-30 US US18/072,501 patent/US11884675B2/en active Active
- 2022-11-30 US US18/072,505 patent/US11912711B2/en active Active
-
2023
- 2023-09-21 US US18/472,147 patent/US12428425B2/en active Active
-
2025
- 2025-10-02 JP JP2025166168A patent/JP2026004465A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12428425B2 (en) | 2025-09-30 |
| CL2022003047A1 (es) | 2023-07-14 |
| JP2023525035A (ja) | 2023-06-14 |
| US11884675B2 (en) | 2024-01-30 |
| US20240182477A1 (en) | 2024-06-06 |
| US20230295170A1 (en) | 2023-09-21 |
| MX2022013842A (es) | 2023-02-22 |
| CA3182105A1 (en) | 2021-11-11 |
| KR20230019822A (ko) | 2023-02-09 |
| CR20220560A (es) | 2023-08-18 |
| EP4146222A1 (en) | 2023-03-15 |
| JP2026004465A (ja) | 2026-01-14 |
| TW202208355A (zh) | 2022-03-01 |
| PE20230846A1 (es) | 2023-05-23 |
| CU24735B1 (es) | 2025-02-07 |
| JP7754846B2 (ja) | 2025-10-15 |
| CN115867284A (zh) | 2023-03-28 |
| BR112022022341A2 (pt) | 2023-01-10 |
| ECSP22089527A (es) | 2023-02-28 |
| EP4146222A4 (en) | 2024-10-09 |
| CU20220064A7 (es) | 2023-06-13 |
| JOP20220296A1 (ar) | 2022-11-02 |
| US20230295169A1 (en) | 2023-09-21 |
| US11912711B2 (en) | 2024-02-27 |
| US20230002390A1 (en) | 2023-01-05 |
| CO2022015930A2 (es) | 2023-01-26 |
| PH12022552949A1 (en) | 2024-02-12 |
| WO2021226629A1 (en) | 2021-11-11 |
| AU2021266805A1 (en) | 2022-12-01 |
| IL297833A (en) | 2023-01-01 |
| US11608344B2 (en) | 2023-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR122010A1 (es) | Compuestos heterocíclicos como receptores desencadenantes expresados en agonistas de células mieloides 2 y métodos de uso | |
| AR121078A1 (es) | Derivados de arilamida con actividad antitumoral | |
| AR120338A1 (es) | Piridazinonas como inhibidores de parp7 | |
| AR111808A1 (es) | Derivados de pirimidina como moduladores del receptor de pge2 | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR117139A1 (es) | Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl) | |
| AR112264A1 (es) | Derivados de oxoftalazina y oxocinolina como antagonistas de los receptores s1p, composición farmacéutica que los comprende y su uso para el tratamiento de enfermedades fibróticas, autoinmunes y proliferativas | |
| AR119657A1 (es) | Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos | |
| AR099955A1 (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados | |
| AR114421A1 (es) | Piperidinil-3-(ariloxi)-propanamidas y propanoatos | |
| AR111807A1 (es) | Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2 | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| AR103566A1 (es) | Compuestos derivados de heteroarilo y heterociclo condensados | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR075367A1 (es) | Inhibidores de glucosilceramida sintasa | |
| AR114420A1 (es) | Derivados de 2,4-diaminoquinazolina y usos médicos de los mismos | |
| AR121299A1 (es) | Inhibidores heterocíclicos de pad4 | |
| AR091185A1 (es) | Derivados de 1,2,4-triazol | |
| CO2025013927A2 (es) | Compuestos de piridazina, su preparación y sus usos terapéuticos | |
| AR127922A1 (es) | Derivados heterocíclicos bicíclicos microbiocidas | |
| AR114564A1 (es) | DERIVADOS DE 2,4,6,7-TETRAHIDRO-PIRAZOLO[3,4-D]PIRIMIDIN-ONA COMO MODULADORES DEL RECEPTOR C5a Y COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE | |
| AR121674A1 (es) | Amidas heterocíclicas como inhibidoras del receptor de tirosina quinasa de tipo iii | |
| AR120649A1 (es) | Antagonistas del receptor de crf y métodos de uso | |
| AR124303A1 (es) | Inhibidores de irak4 |